Skip to content

Released Aug 14, 2025, after the close

10-Q filed Aug 14, 2025, 45 days after period end · 0001410578-25-001809

Q2 2025 · 10-Q
Revenue$1.98M+1.4% vs Q2 2024−15.4% vs Q1 2025
Net Income-$15.70MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.52N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$1,618,000+13.9%
Operating Income-$13,806,000N/M
Operating Cash Flowderived-$13,744,000N/M
Margins · derived
Gross margin81.7%+8.9 pt vs Q2 2024
Operating margin-696.9%−295.4 pt vs Q2 2024
Net margin-792.3%−438.0 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024
Revenue$1.98M$1.95M
Net Income-$15.70M-$6.92M
EPS Diluted-$0.52$0.28

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR